Preclinical experiments in human cells and mice suggest CBD may prevent the replication of SARSCoV2, but the authors advise caution until completion of a clinical trial, citing questions on dosage, formulation, and mode of delivery. ScienceAdvances
). The project described was supported by the National Institute of General Medical Sciences, 5U54GM104942-04. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The analysis used only de-identified data . We gratefully acknowledge contributions from the following N3C core teams:Workstream, subgroup and administrative leaders
: Melissa A. Haendel, Tellen D. Bennett, Christopher G. Chute, David A. Eichmann, Justin Guinney, Warren A. Kibbe, Hongfang Liu, Philip R.O. Payne, Emily R. Pfaff, Peter N. Robinson, Joel H. Saltz, Heidi Spratt, Justin Starren, Christine Suver, Adam B. Wilcox, Andrew E. Williams, Chunlei WuIndividuals at the sites who are responsible for creating the datasets and submitting data to N3C: Christopher G. Chute, Emily R. Pfaff, Davera Gabriel, Stephanie S. Hong, Kristin Kostka, Harold P.
• Publication Committee Management Team: Mary Morrison Saltz, Christine Suver, Christopher G. Chute, Melissa A. Haendel, Julie A. McMurry, Andréa M. Volz, Anita Walden: Carolyn Bramante, Jeremy Richard Harper, Wenndy Hernandez, Farrukh M Koraishy, Federico Mariona, Saidulu Mattapally, Amit Saha, Satyanarayana Vedula.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Why scientists are racing to develop more COVID antiviralsThe first crop of antivirals against SARS-CoV-2 is promising. But new drugs will be needed to counter the looming threat of resistance.
Lire la suite »
Why scientists are racing to develop more COVID antiviralsThe first crop of antivirals against SARS-CoV-2 is promising. But new drugs will be needed to counter the looming threat of resistance.
Lire la suite »
Why scientists are racing to develop more COVID antiviralsThe first crop of antivirals against SARS-CoV-2 is promising. But new drugs will be needed to counter the looming threat of resistance.
Lire la suite »
How does Omicron spread so fast? A high viral load isn’t the answerData on viral levels point to immune evasion as a cause of the variant’s transmissibility.
Lire la suite »